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ABSTRACT Dengue virus (DENV) is the most geographically widespread arbovirus causing dengue disease epidemics in
tropical and subtropical regions. Nature provides abundant plants as a source for lead molecules against various diseases
including DENV infection. We investigated the antiviral effect of curcumin and 6‐gingerol, the major active constituent
of turmeric (Curcuma longa Linn.) and ginger (Zingiber officinale Roscoe), respectively, against all four serotypes of DENV
infecting human lung epithelial carcinoma (A549) cell line in vitro. Both compounds generated cell cytotoxicity to A549 cells
at CC50 values of 108 µM for curcumin and 210 µM for 6‐gingerol. The compound curcumin showed antiviral properties
as described by IC50 of 20.60, 13.95, 25.54, and 12.35 µM, while 6‐gingerol of 14.70, 14.17, 78.76, and 112.84 µM for
DENV‐1, ‐2, ‐3, and ‐4, respectively. Different levels of antiviral properties were observed between DENV serotypes. Our
findings suggest that the antiviral assay of compounds against DENV should be performed to all four serotypes and not
limited to a particular serotype. In conclusion, curcumin and 6‐gingerol exhibit antiviral properties against DENV infection
and could provide a new therapeutic approach for dengue disease treatment strategies.
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1. Introduction
Dengue virus (DENV) is considered the most geographi­
cally widespread arthropod­borne virus with an increased
frequency of epidemics and severe disease manifestation
in hyperendemic countries (Guzman and Harris 2015). It
is estimated that 390 million cases of DENV infections oc­
cur worldwide annually (Bhatt et al. 2013; Guzman and
Harris 2015). Over the past 50 years, the world has ex­
perienced a dramatic increase in dengue incidence to al­
most 30­folds (Guo et al. 2017), facilitated by virus trans­
mission predominantly by Aedes aegypti and to a lesser
extent Aedes albopticus mosquito vectors (Guzman et al.
2016). The four DENV serotypes (DENV­1, ­2, ­3, and
­4) can cause a wide range of disease in human, from
asymptomatic, classical fever Dengue Fever, to the life­
threatening conditions Dengue Hemorrhagic Fever and
Dengue Shock Syndrome (Martina et al. 2009).
The current disease management for DENV infection
is limited to early detection, fluid replacement, and symp­
tomatic therapy, although research has proven the associ­
ation of viral load with the severity of the disease in the
patients (Wang et al. 2003). The first­ever dengue vaccine
Dengvaxia (CYD­TDV) still has limited use in the target
population below nine years old (Dighe et al. 2019) and
the development of anti­DENV drugs has been in a slow
process. There is no licensed antiviral therapy available
to date and only four small molecule anti­DENV drugs
have entered phase I and phase II clinical trials. Although
these drugs meet the required safety profile, they could
not reduce viral load as expected (Tian et al. 2018). With
the current unavailability of antiviral therapy for DENV
infection, a search for compounds having antiviral effect
needs to be established. One of the possible sources of a
compound with anti­DENV activities will be from natural
sources.
Indonesia has been known to have an abundant source
of medicinal plants. Turmeric (Curcuma longa Linn.) and
ginger (Zingiber officinale Roscoe), both from the fam­
ily Zingiberaceae, have been used by generations of peo­
ple around the world as a dietary spice, food preservative,
and traditional herbal medicine (Soleimani et al. 2018).
Turmeric contains a major active constituent called cur­
cumin (Soleimani et al. 2018), while ginger contains 6­
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gingerol (Kubra and Rao 2012; Wang et al. 2014). Re­
searchers have shown the antioxidant, anti­inflammatory,
anti­neoplastic, anti­microbial, and antiviral abilities of
curcumin (Gupta et al. 2013; Kocaadam and Şanlier 2017)
and 6­gingerol (Chrubasik et al. 2005). Curcumin, which
is considered a non­mutagenic and non­genotoxic agent
(Soleimani et al. 2018), has shown its antiviral properties
against Flaviviridae viruses such as Zika Virus (Mounce
et al. 2017), Hepatitis C Virus (HCV) (Anggakusuma et al.
2014), Japanese Encephalitis Virus (Dutta et al. 2009), and
DENV­2 (Padilla­S et al. 2014). Fresh ginger has shown
its inhibitory effect against human respiratory syncytial
virus (HRSV) (Chang et al. 2013) and HCV (El­adawi
et al. 2011).
Human alveolar epithelial A549 cells have been
proven suitable for use as a DENV infection model in
vitro (Yohan et al. 2014). The use of A549 cell line in
DENV research was based on the evidence of viral anti­
gen detection in macrophages and vascular endothelial
cells of the lung (Jessie et al. 2004). The antiviral ef­
fect of curcumin and 6­gingerol to DENV has been re­
ported although limited to a particular serotype (Padilla­
S et al. 2014; Sharma et al. 2015). The differing genetic
of DENV serotypes may cause differences in their viru­
lence (Holmes and Burch 2000). Hence, an antiviral study
against all four DENV serotypes in human cells will give
more insights into dengue pathogenesis. In this study, we
investigated the antiviral effect of curcumin and 6­gingerol
on the growth of all four DENV serotypes in human A549
cell line. Findings from this study may be beneficial for
the development of anti­DENV drug therapy from natural
resources as alternative therapeutic approach for dengue
disease.
2. Materials and Methods
2.1. DENV serotypes
Four DENV serotypes of Indonesian isolates were used.
All virus stocks were generated from a low­passage num­
ber (maximum of five passages) of the virus in Vero
cells. The DENV­1 strain JMB­034 was isolated from a
dengue patient in Jambi (Haryanto et al. 2016). The other
serotypes DENV­2 strain SUB­011, DENV­3 strain SUB­
006, and DENV­4 strain SUB­007 were isolated from pa­
tients in Surabaya, East Java (Aryati et al. 2013; Ward­
hani et al. 2017). The harvested culture supernatants con­
taining viable DENV were stored at ­80 °C until use and
their titers were measured using standard plaque assay
method in BHK21 cells, as described previously (Yohan
et al. 2014; Sasmono et al. 2015).
2.2. Cell cultivation and maintenance
Cell lines were obtained from ATCC. The human (Homo
sapiens) alveolar epithelial carcinoma A549 (ATCC CCL­
185) and Syrian golden hamster (Mesocricetus auratus) fi­
broblast BHK­21 (ATCC CCL­10) cells were grown and
maintained in RPMI 1640Medium (Gibco­Thermo Fisher
Scientific, CA, USA). The African green monkey (Cerco­
pithecus aethiops) Vero (ATCC CCL­81) cells were main­
tained inMinimum Essential Medium (Gibco). The media
were supplemented with 10% fetal bovine serum (FBS),
2 mM of L­glutamine, 100 U/mL of penicillin, and 100
μg/mL of streptomycin (all fromGibco). Cells were main­
tained in a humidified 37 °C incubator with 5% CO2 sup­
plementation (Yohan et al. 2014).
2.3. A549 cell viability test
Curcumin (≥ 65%, HPLC) and 6­gingerol (≥ 98%, HPLC)
were purchased from Sigma­Aldrich in powder and
lyophilized forms, respectively. Both compounds were
solubilized using dimethyl sulfoxide (DMSO) (Sigma­
Aldrich, USA) as a vehicle into stock solutions of known
molarity. The stock solutions were then diluted into work­
ing solutions using RPMI medium supplemented with
10% FBS. The cytotoxicity of the compounds was tested
in A549 cells, seeded 1×105 cells/well of 96­well plate and
grown overnight at 37 °C, 5% CO2. Serially diluted com­
pounds were added into the cells monolayer in triplicate
and tested with 3­(4,5­dimethylthiazol­2­yl)­2,5­diphenyl
tetrazolium bromide (MTT) using the MTT Cell Prolifer­
ation Assay Kit (Trevigen, Gaithersburg, MD, USA) after
48 h of incubation at 37 °C, 5% CO2, according to the
protocol described by the manufacturer. Following the
formation of formazan complexes, the plate was read at
570 nm using a microplate reader. The percentage of cell
viability was measured as a comparison to the medium­
only controls. A dose­response curve was obtained using
non­linear regression (curve fit) and the cytotoxic concen­
tration was calculated as median cell cytotoxicity (CC50)
in which the concentration of compound that reduced the
cell’s viability by half.
2.4. DENV antiviral activity testing
The A549 cells were seeded at 1×105 cells/well in 96­well
plate and subjected to infection with DENV­1, DENV­2,
DENV­3, or DENV­4 with multiplicity of infection (MOI)
value of 1, described hypothetically as one virus particle
per cell. Compounds treatment was done using 10, 25,
and 50 μM of curcumin and 50, 100, and 200 μM of 6­
gingerol, selected as sub­cytotoxic concentrations follow­
ing the CC50 values determined from A549 cell viability
test. Treatment of cells with calculated concentrations of
compounds was done using co­treatment method, where
the mixture of DENV and compounds was added to cell
monolayer and allowed to react at 37 °C, 5% CO2 for 48 h,
without removal of inoculant or wash steps, as described
previously (Chen et al. 2013). Following the incubation
period, the supernatant was transferred into microtubes for
the virus titration using plaque assay in BHK21 cells. The
calculated virus titer was normalized to the medium only
control (without compound or 0 µM) and presented as a
percent of inhibition. The median inhibitory concentration
(IC50) was measured as the concentration of compound
that can inhibit 50% of virus titer. A vehicle control is
used to monitor the effect of DMSO diluent in the system.
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FIGURE 1 . Cell cytotoxicity of different concentrations of curcumin (a) and 6‐gingerol (b) to A549 cells, as determined by CC50. Both
compounds showed significant dose‐dependent cell cytotoxicity. Treatment of cells with 0.1% of DMSO was used as vehicle control.
The vehicle control was prepared as 0.1% v/v of DMSO, a
concentration that was higher than the highest concentra­
tion of compounds in the testing.
2.5. Statistical analysis, CC50 and IC50 calculations
Statistical analyses were conducted using SPSS Statis­
tics software version 17.0 (SPSS Inc., USA). Mean and
standard error of mean (SEM) from three independent
experiments were calculated. The comparison between
groups in experimental results was analyzed using one­
way ANOVA, followed by Tukey’s post hoc test. A p­
value less than 0.05 was considered as statistically signifi­
cant. TheCC50 and IC50 valueswere calculated usingAAT
Bioquest Quest Graph IC50 calculator (available online
at https://www.aatbio.com/tools/ic50­calculator) based on
the four­parameters logistic equation to generate a sigmoid
function.
3. Results and Discussion
3.1. Cytotoxicity of curcumin and 6‐Gingerol to A549
cells
The cells’ cytotoxicity properties of curcumin and 6­
gingerol were measured using standard MTT assay for
measurement of cells’ viability. Both curcumin and 6­
gingerol reduced the viability of A549 cells in a dose de­
pendent manner. The median cell cytotoxicity CC50 of
curcumin and 6­gingerol were measured at 108 μM and
210 μM, respectively (Figure 1). Both curcumin and 6­
TABLE 1 The antiviral activities of curcumin and 6‐gingerol against
four DENV serotypes as determined by median inhibitory concen‐
tration (IC50).
Compound
IC50 of compound to DENV challenge (µM)
DENV‐1 DENV‐2 DENV‐3 DENV‐4
Curcumin 20.60 13.95 25.54 12.35
6‐gingerol 14.70 14.17 78.76 112.84
gingerol significantly reduced the A549 cell viability in a
dose­dependent manner (R2=0.9132, p = 0.0029 and R2=
0.9149, p = 0.0001, for curcumin and 6­gingerol, respec­
tively).
3.2. Antiviral activities of curcumin and 6‐gingerol
against DENV
Following the CC50 data, the antiviral testing of cur­
cumin and 6­gingerol was set at sub­cytotoxic concentra­
tions. Curcumin and 6­gingerol significantly inhibited the
growth of all DENV serotypes (Figure 2 and 3, respec­
tively). For curcumin, all concentrations tested signifi­
cantly inhibited the growth of all DENV serotypes com­
pared to the medium­only group (p < 0.05), except in two
experimental conditions at 10 µM and 25 µM in DENV­3
(Figure 2). On the other hand, for 6­gingerol, all concen­
trations tested show a significant reduction in the growth of
all DENV serotypes (p < 0.05) except at 50 µM inDENV­3
(Figure 3).
The inhibition profiles were increased along with the
increasing concentration of compounds compared to the
medium only control. Vehicle control resulted in not sig­
nificant reduction of virus titers compared to control (data
not shown). We observed a variable median inhibitory
concentration IC50 results for each DENV serotype (Table
1).
The compound curcumin has IC50 of 20.60, 13.95,
25.54, and 12.35 µM against DENV­1, ­2, ­3, and ­4, re­
spectively (Table 1). Curcumin showed the highest an­
tiviral activities to DENV­4 compared to other DENV
serotypes. Nevertheless, IC50 values for all serotypes were
quite similar. For 6­gingerol, the compound was inhibit­
ing the growth of DENV with IC50 values of 14.70, 14.17,
78.76, and 112.84 µM for DENV­1, ­2, ­3, and ­4, re­
spectively (Table 1). While highest antiviral activity was
observed for DENV­2, the compound 6­gingerol showed
higher antiviral potency for DENV­1 and DENV­2 com­
pared to DENV­3 and DENV­4.
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FIGURE 2 Antiviral activity profiles of curcumin against all four
DENV serotypes, measured as percentage of viable virus titer in
treatment groups to the medium only control after 48 h of assay in
A549 cells. ns, not significant; *, p < 0.05.
3.3. Discussion
The significant increase in dengue research during the past
decades covers topics on dengue virology, pathogenesis,
and immunology and progress in developing antivirals,
vaccines, and new vector­control strategies that are impor­
tant for dengue control and prevention (Guzman and Har­
ris 2015). We tested the antiviral properties of curcumin
and 6­gingerol against all four serotypes of wild strain
DENV on A549 cell lines. The A549 cell line was used
for its susceptibility to DENV infection and showed supe­
rior suitability compared to other human cell lines (Yohan
et al. 2014).
As an active compound from nature, curcumin and 6­
gingerol can also be toxic and induce apoptosis to cells
(Kaushik et al. 2012; Impheng et al. 2015). We found that
curcumin has cytotoxic property although it did not signif­
icantly affect A549 cells’ viability in concentrations up to
50 μM with CC50 of 108 μM after 48 h of cell treatment
(Figure 1a), a result that is comparable to a previous study
by Kaushik et al. (2012). In the other hand, 6­gingerol
showed cytotoxicity to A549 cells with CC50 of 210 μM
(Figure 1b), comparable to other result observed elsewhere
(Kim et al. 2008).
Antiviral activities of curcumin against DENV­2 has
been reported (Padilla­S et al. 2014; Balasubramanian
et al. 2019). The activity against DENV or enveloped
virus is believed through the inhibition of Ubiquitin Pro­
teasome System (UPS) (Chen et al. 2013; Padilla­S et al.
FIGURE 3 Antiviral activity profiles of 6‐gingerol against all four
DENV serotypes, measured as percentage of viable virus titer in
treatment groups to the medium only control after 48 h of assay in
A549 cells. ns, not significant; *, p < 0.05.
2014) which plays a role in viral replication (Glickman and
Ciechanover 2002). In this study, we found that curcumin
could inhibit all four DENV serotypes in the same manner
(Figure 2), although different levels of IC50 was observed
for each serotype (Table 1). Our result suggested similar
antiviral potency of curcumin to all DENV serotypes. The
effect of curcumin to DENV­2 was in accordance with pre­
vious result by Padilla­S et al. (2014). To the best of our
knowledge, this is the first study to explore the antiviral
ability of curcumin against all four serotypes of wild­type
DENVs. The possible mechanisms of curcumin’s antiviral
properties include membrane­disturbing properties (Chen
et al. 2013), altering membrane fluidity (Anggakusuma
et al. 2014), and inhibiting cell binding (Mounce et al.
2017).
The compound 6­gingerol is known to exhibit a va­
riety of biological activities including anticancer, anti­
inflammation, and antioxidant (Wang et al. 2014). In
this study, 6­gingerol, also revealed anti­DENV proper­
ties shown by the reduction of viral growth along with
the increasing 6­gingerol concentration in the in vitro sys­
tem (Figure 3). Previous study demonstrated the ability
of fresh lipophilic juice of ginger to cause complete inhi­
bition of HCV replication, a member of Flavivirus family
likeDENV (El­adawi et al. 2011). Fresh ginger is effective
against HRSV­induced plaque formation on HepG2 and
A549 cell lines by blocking viral attachment and internal­
ization by interfering G protein and F protein (Chang et al.
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2013). The administration of 6­gingerol wasmanifested as
inhibition of fatty acid synthase (FASN) expression (Im­
pheng et al. 2015), which is a biosynthetic pathway to es­
tablish DENV replication complexes (Heaton et al. 2010).
The aqueous extract of ginger rhizome inhibited the ac­
tivity of matrix metalloproteinase (MMP)­2 and MMP­9,
while upregulating the expression of tissue inhibitor met­
alloproteinase (TIMP)­1 and TIMP­2 in DENV infected
cells (Sharma et al. 2015). Interestingly, the antiviral ac­
tivity of 6­gingerol was found to be higher in DENV­1 and
­2 compared to DENV­3 and ­4. The fact that 6­gingerol
has different antiviral properties to four DENV serotypes
is of merit for further confirmatory exploration whether
different genetic of DENV serotypes attributed to these
findings.
Our results add information on the antiviral proper­
ties of curcumin and 6­gingerol against all four serotypes
of DENV. In addition, we promote that antiviral assay of
compounds against DENV should be performed to all four
serotypes and not limited to a particular serotype. Never­
theless, our study has limitations. The study design was
aimed only to inspect the antiviral properties of curcumin
and 6­gingerol in four DENV serotypes. The biological
pathway mechanisms underlying the virus inhibition ef­
fect were not sought. More in­depth studies are needed
to confirm our findings. In addition, the availability of
different compound sources with different purities in the
market may also give impact on the results generated. To
the best of our knowledge, this is the first study describing
the antiviral effects of curcumin and 6­gingerol to all four
DENV serotypes.
4. Conclusions
In conclusion, curcumin, the major active compound of
turmeric and 6­gingerol, the major active constituents of
ginger, have shown antiviral activities against all four
serotypes of DENV. Curcumin and 6­gingerol may have
potentials in the development of anti­DENV drug therapy
from natural resources and could provide an alternative
therapeutic approach for dengue disease treatment strate­
gies.
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